Last reviewed · How we verify

NCT03609437: ESUS

Impaired Endothelial Integrity in Patients With Embolic Stroke of Undetermined Source (ESUS)

Active, enrolled Last updated 15 July 2025
What this trial tests

trial in Embolic Stroke of Undetermined Source in 215 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 January 2018
Primary endpoint
30 October 2025
30 June 2026

Quick facts

Lead sponsorUniversity of Athens
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment215
Start date1 January 2018
Primary completion30 October 2025
Estimated completion30 June 2026
Sites1 location across Greece

Conditions studied

Sponsor

University of Athens

Who can join

Adults 18 to 75, any sex, with Embolic Stroke of Undetermined Source or Endothelial Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will measure endothelial glycocalyx, aortic elastic properties, oxidative stress, and their association with left ventricular (LV) and left atrial (LA) function in ESUS, cardioembolic, atherosclerotic, lacunar strokes and age- and sex-adjusted healthy individuals.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Impaired Arterial Elastic Properties and Endothelial Glycocalyx in Patients with Embolic Stroke of Undetermined Source.
    Ikonomidis I, Frogoudaki A, Vrettou AR, Andreou I, et al · · 2019 · cited 18× · PMID 31421641 · DOI 10.1055/s-0039-1694752

Verify or expand the search:

Other recruiting trials for Embolic Stroke of Undetermined Source

Currently open trials in the same condition.

Other University of Athens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03609437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing